MedTrace Logo

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

NCT01959412 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2015-05-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.

Conditions

Interventions

DRUG

Indacaterol 27.5 mcg

indacaterol 27.5 mcg twice daily inhaled once via inhaler

DRUG

Indacaterol 37.5

Indacaterol 37.5 mcg once daily, inhaled once via inhaler

DRUG

Indacaterol 55 mcg

Indacaterol 55 mcg once daily, inhaled once via inhaler

DRUG

Indacaterol 75 mcg

Indacaterol 75 mcg once daily, inhaled once via inhaler

DRUG

Indacaterol 150 mcg

Indacaterol 150 mcg once daily, inhaled once via inhaler

DRUG

Placebo

Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959412 on ClinicalTrials.gov